Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:3702 |
| Name | cervical adenocarcinoma |
| Definition | A cervix carcinoma that derives_from epithelial cells of glandular origin. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Xrefs |
SNOMEDCT_US_2023_03_01:254887002
|
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer cervical cancer cervix carcinoma cervical adenocarcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| FGFR2 amp FGFR2 mut | Zoligratinib | cervical adenocarcinoma | predicted - sensitive | detail... |
| CD274 positive | Camrelizumab | cervical adenocarcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01101451 | Phase III | Cisplatin | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery | Completed | USA | 2 |
| NCT02257528 | Phase II | Nivolumab | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | Active, not recruiting | USA | 0 |
| NCT02348398 | Phase II | Pazopanib + Topotecan | Phase II Study of Pazopanib and Topotecan in Cervical Cancer | Withdrawn | 0 | |
| NCT02466971 | Phase III | Cisplatin Cisplatin + Triapine | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | Active, not recruiting | USA | CAN | 1 |
| NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Unknown status | USA | ITA | GBR | ESP | 2 |
| NCT02595879 | Phase I | Cisplatin + Triapine | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer | Active, not recruiting | USA | 0 |
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT02853604 | Phase III | ADXS11-001 | Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV) | Terminated | USA | POL | ESP | CAN | BRA | ARG | 8 |
| NCT03108495 | Phase II | LN-145 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma | Terminated | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | 0 |
| NCT03367871 | Phase II | Cisplatin + Paclitaxel + Pembrolizumab | Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer | Terminated | USA | 0 |
| NCT03438396 | Phase II | Tisotumab vedotin-tftv | A Trial of Tisotumab Vedotin in Cervical Cancer | Completed | USA | SWE | ITA | ESP | DNK | DEU | CZE | BEL | 0 |
| NCT03495882 | Phase Ib/II | Balstilimab + Zalifrelimab | Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | Completed | USA | POL | HUN | ESP | BRA | AUS | 3 |
| NCT03556839 | Phase III | Atezolizumab + Bevacizumab + Cisplatin + Paclitaxel Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) | Active, not recruiting | USA | SWE | NOR | ITA | FRA | ESP | DEU | 1 |
| NCT03612791 | Phase II | Cisplatin Atezolizumab + Cisplatin | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) | Completed | FRA | 0 |
| NCT03635567 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | Completed | USA | TUR | ITA | ISR | FRA | ESP | DEU | CAN | AUS | ARG | 9 |
| NCT03644342 | Phase Ib/II | Niraparib | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX) | Terminated | USA | 0 |
| NCT03738228 | Phase I | Atezolizumab + Cisplatin | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | Completed | USA | 0 |
| NCT03786081 | Phase Ib/II | Bevacizumab + Tisotumab vedotin-tftv Carboplatin + Tisotumab vedotin-tftv Pembrolizumab + Tisotumab vedotin-tftv | Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer | Active, not recruiting | USA | TUR | NLD | ITA | IRL | GBR | ESP | DNK | CZE | BEL | 0 |
| NCT03830866 | Phase III | Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) | Completed | USA | POL | HUN | BRA | 11 |
| NCT03833479 | Phase II | Dostarlimab-gxly | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC) | Active, not recruiting | TUR | ESP | 0 |
| NCT03894215 | Phase II | Balstilimab Balstilimab + Zalifrelimab | Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | Active, not recruiting | USA | BRA | 5 |
| NCT04065269 | Phase II | Ceralasertib + Olaparib Ceralasertib | ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) | Active, not recruiting | GBR | CAN | 0 |
| NCT04152499 | Phase Ib/II | Sacituzumab tirumotecan | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Active, not recruiting | USA | TUR | CAN | 3 |
| NCT04205799 | Phase II | Cabozantinib | Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure (CABOCOL-01) | Completed | FRA | 0 |
| NCT04221945 | Phase III | Cisplatin + Pembrolizumab Cisplatin | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11) | Completed | USA | TUR | SWE | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 11 |
| NCT04230954 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | Terminated | USA | 0 |
| NCT04238988 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (MITO CERV 3) | Unknown status | ITA | 0 |
| NCT04246489 | Phase II | Bintrafusp alfa | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | Completed | USA | HUN | FRA | ESP | BRA | BEL | AUS | ARG | 4 |
| NCT04300647 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) | Completed | USA | POL | ITA | GBR | FRA | ESP | CAN | BRA | AUS | 8 |
| NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | POL | LVA | LTU | HRV | CHE | BRA | 2 |
| NCT04405349 | Phase II | Atezolizumab + VB10.16 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | Completed | POL | NOR | DEU | CZE | BGR | BEL | 0 |
| NCT04487587 | Phase II | Cediranib + Olaparib | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (COMICE) | Active, not recruiting | GBR | 0 |
| NCT04551950 | Phase I | Bevacizumab + Bintrafusp alfa + Carboplatin + Paclitaxel Bevacizumab + Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin Bintrafusp alfa + Carboplatin + Paclitaxel | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTRAPID 046) | Completed | USA | ESP | 1 |
| NCT04630353 | Phase I | HB-201 | A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer | Terminated | USA | 0 |
| NCT04652076 | Phase Ib/II | Carboplatin + NP137 + Paclitaxel Trevatide + Pembrolizumab NP137 + Pembrolizumab Carboplatin + NP137 + Paclitaxel Carboplatin + Paclitaxel | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET) | Active, not recruiting | FRA | 0 |
| NCT04697628 | Phase III | Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) | Completed | USA | SWE | POL | NOR | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | ARG | 7 |
| NCT04943627 | Phase III | Topotecan Balstilimab Gemcitabine Irinotecan Pemetrexed Disodium Vinorelbine | Balstilimab in Patients With Recurrent Cervical Cancer. | Withdrawn | USA | 1 |
| NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Completed | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
| NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
| NCT05475171 | Phase II | MGD019 | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | Recruiting | USA | 0 |
| NCT05492123 | Phase II | Ipilimumab + Nivolumab Cisplatin Cisplatin + Nivolumab Carboplatin + Nivolumab Carboplatin | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | Recruiting | BRA | 0 |
| NCT05521997 | Phase II | Cisplatin + Telaglenastat Cisplatin | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | Not yet recruiting | USA | 0 |
| NCT05527184 | Phase I | IMGN151 | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Active, not recruiting | USA | NLD | ITA | IRL | FRA | ESP | DEU | CAN | BEL | AUS | 0 |
| NCT05914116 | Phase Ib/II | DB-1311 + Enzalutamide Abiraterone + DB-1311 DB-1311 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
| NCT06079671 | Phase III | MEDI5752 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical) | Recruiting | USA | TUR | POL | NOR | ITA | ESP | DNK | DEU | CAN | BRA | 9 |
| NCT06099418 | Phase II | VB10.16 Atezolizumab + VB10.16 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | Withdrawn | 0 | |
| NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | NOR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
| NCT06266338 | Phase II | Lenvatinib + Pembrolizumab | Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) | Recruiting | USA | 0 |
| NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT06459180 | Phase III | Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Topotecan Sacituzumab tirumotecan | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
| NCT06535607 | Phase II | MEDI5752 Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Fluorouracil + MEDI5752 Cisplatin + Fluorouracil + MEDI5752 | Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (eVOLVE-02) | Recruiting | USA | BRA | 4 |
| NCT06543576 | Phase Ib/II | Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | Recruiting | USA | 0 |
| NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Recruiting | USA | ITA | FRA | ESP | DNK | BEL | 3 |
| NCT06670911 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Paclitaxel + Pembrolizumab | Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. (ACCESS-I) | Recruiting | BRA | 0 |
| NCT06865677 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas | Terminated | USA | 0 |
| NCT06925724 | Phase II | Ivonescimab | A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Recruiting | USA | 0 |
| NCT06953089 | Phase II | DB-1305 + DB-1311 BNT327 + DB-1311 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
| NCT07061977 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Recruiting | USA | 0 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | BEL | AUS | 0 |
| NCT07216703 | Phase III | Pembrolizumab + Sacituzumab tirumotecan Cisplatin + Paclitaxel + Pembrolizumab Bevacizumab + Pembrolizumab + Sacituzumab tirumotecan Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Pembrolizumab | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | Recruiting | USA | SWE | POL | ITA | ISR | HUN | ESP | CZE | CAN | BEL | ARG | 3 |
| NCT07368985 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | Not yet recruiting | NLD | 0 |